Clinical trial
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
NCT00293488 · Progen Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00293488 |
|---|---|
| Title | SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma |
| Official title | An Open Label Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of SL-11047 in Patients With Refractory Lymphoma |
| Lead sponsor | Progen Pharmaceuticals, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | polyamine analogue PG11047 |
| Enrollment | 20 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2008 |
| First posted | Feb 17, 2006 |
| Last update posted | Jun 23, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: